28 February 2020

Reig Jofre reaches € 200 million in revenue and closes 2019 with a growth of 11% in sales and 20% in EBITDA

5 February 2020

The use of chondroprotectors (SYSADOA) would enable the NHS to avoid around 20,000 adverse effects per year, with an economic saving of more than 40 million Euros over three years

27 January 2020

Reig Jofre reaches a new milestone: 5 million vials of injectable Remifentanil marketed in Japan

22 January 2020

Publication schedule for 2020 results

20 January 2020

Forté Pharma, Reig Jofre’s line of nutritional supplements, launches EXPERT LIFT’ FILLER

8 January 2020

Begining of the liquidity contract

7 January 2020

End of the share buy-back program

30 December 2019

Transactions within the share buy-back program

23 December 2019

Transactions within the share buy-back program

19 December 2019

Reig Jofre begins trading on the IBEX SMALL CAP

18 December 2019

The subsidiary Reig Jofre Europe begins the marketing of its products in Myanmar

16 December 2019

Transactions within the share buy-back program

9 December 2019

Transactions within the share buy-back program

2 December 2019

Transactions within the share buy-back program

25 November 2019

Transactions within the share buy-back program

22 November 2019

Reig Jofre, Internationalization of Spanish Healthcare Activity Award

18 November 2019

Transactions within the share buy-back program

14 November 2019

Reig Jofre closes the third quarter of 2019 with an accumulated growth of 10% in sales and 17% in EBITDA

12 November 2019

Reig Jofre and Ojer Pharma obtain the first European authorization for the commercialization of their innovative antibiotic Impetine Gel

11 November 2019

Transactions within the share buy-back program